{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T11:34:02Z","timestamp":1768995242630,"version":"3.49.0"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015640","name":"Huazhong University of Science and Technology Tongji Medical College Tongji Hospital","doi-asserted-by":"publisher","award":["ZD24-MN"],"award-info":[{"award-number":["ZD24-MN"]}],"id":[{"id":"10.13039\/501100015640","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82403182"],"award-info":[{"award-number":["82403182"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472857"],"award-info":[{"award-number":["82472857"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ijbiomac.2025.149810","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:03:48Z","timestamp":1766189028000},"page":"149810","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P2","title":["Restraining SRD5A1 combined with BRD4 inhibitor delaying prostate cancer progression by decreasing AR expression"],"prefix":"10.1016","volume":"338","author":[{"given":"Yifan","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duocheng","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifan","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denglong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenye","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengdang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149810_bb0005","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.149810_bb0010","first-page":"115","article-title":"Cancer statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA Cancer J. Clin."},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.149810_bb0015","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1002\/cncr.23304","article-title":"Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect","volume":"112","author":"Ross","year":"2008","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.149810_bb0020","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/cncr.31846","article-title":"Annual report to the nation on the status of cancer, part II: recent changes in prostate cancer trends and disease characteristics","volume":"125","author":"Curry","year":"2019","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.149810_bb0025","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer","volume":"79","author":"Cornford","year":"2021","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.149810_bb0030","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1210\/jc.2012-2912","article-title":"Liquid chromatography-tandem mass spectrometry analysis of human adrenal vein 19-carbon steroids before and after ACTH stimulation","volume":"98","author":"Rege","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"10","key":"10.1016\/j.ijbiomac.2025.149810_bb0035","doi-asserted-by":"crossref","DOI":"10.1172\/JCI146777","article-title":"Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth","volume":"131","author":"Nyquist","year":"2021","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149810_bb0040","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-020-00243-0","article-title":"Prostate cancer","volume":"7","author":"Rebello","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"10","key":"10.1016\/j.ijbiomac.2025.149810_bb0045","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1210\/jc.2006-0968","article-title":"Persistent intraprostatic androgen concentrations after medical castration in healthy men","volume":"91","author":"Page","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"Pt B","key":"10.1016\/j.ijbiomac.2025.149810_bb0050","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jsbmb.2016.07.009","article-title":"Androgen biosynthesis during minipuberty favors the backdoor pathway over the classic pathway: insights into enzyme activities and steroid fluxes in healthy infants during the first year of life from the urinary steroid metabolome","volume":"165","author":"Dhayat","year":"2017","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.149810_bb0055","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1001\/jamaoncol.2017.3159","article-title":"HSD3B1 and response to a nonsteroidal CYP17A1 inhibitor in castration-resistant prostate cancer","volume":"4","author":"Almassi","year":"2018","journal-title":"JAMA Oncol."},{"issue":"10","key":"10.1016\/j.ijbiomac.2025.149810_bb0060","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1210\/endo.140.10.7038","article-title":"Induction of 3beta-hydroxysteroid dehydrogenase\/isomerase type 1 expression by interleukin-4 in human normal prostate epithelial cells, immortalized keratinocytes, colon, and cervix cancer cell lines","volume":"140","author":"Gingras","year":"1999","journal-title":"Endocrinology"},{"issue":"8","key":"10.1016\/j.ijbiomac.2025.149810_bb0065","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1210\/mend-5-8-1147","article-title":"Structure and expression of a new complementary DNA encoding the almost exclusive 3 beta-hydroxysteroid dehydrogenase\/delta 5-delta 4-isomerase in human adrenals and gonads","volume":"5","author":"Rheaume","year":"1991","journal-title":"Mol. Endocrinol."},{"issue":"21","key":"10.1016\/j.ijbiomac.2025.149810_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232113521","article-title":"Androgen metabolism and response in prostate cancer anti-androgen therapy resistance","volume":"23","author":"Zhang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.149810_bb0075","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.juro.2013.03.024","article-title":"SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5alpha-reductase inhibitors and alpha-adrenergic receptor antagonists","volume":"190","author":"Gu","year":"2013","journal-title":"J. Urol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149810_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/jme.0.0250001","article-title":"Intracrinology: role of the family of 17 beta-hydroxysteroid dehydrogenases in human physiology and disease","volume":"25","author":"Labrie","year":"2000","journal-title":"J. Mol. Endocrinol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.149810_bb0085","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/pros.20188","article-title":"Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer","volume":"63","author":"Thomas","year":"2005","journal-title":"Prostate"},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.149810_bb0090","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1158\/0008-5472.CAN-05-4000","article-title":"Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer","volume":"66","author":"Stanbrough","year":"2006","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.ijbiomac.2025.149810_bb0095","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1158\/0008-5472.CAN-08-0249","article-title":"Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth","volume":"68","author":"Montgomery","year":"2008","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149810_bb0100","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/(SICI)1097-0215(19960328)66:1<37::AID-IJC7>3.0.CO;2-#","article-title":"Characterization of 17beta-hydroxysteroid dehydrogenase isoenzyme expression in benign and malignant human prostate","volume":"66","author":"Elo","year":"1996","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149810_bb0105","doi-asserted-by":"crossref","first-page":"188","DOI":"10.5534\/wjmh.230327","article-title":"Comparison of finasteride and dutasteride on risk of prostate cancer in patients with benign prostatic hyperplasia: a pooled analysis of 15 real-world databases","volume":"43","author":"Yang","year":"2025","journal-title":"World J. Mens Health"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149810_bb0110","first-page":"133","article-title":"Effect of dutasteride on castration-resistant prostate cancer","volume":"8","author":"Azuma","year":"2018","journal-title":"Mol Clin Oncol"},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.149810_bb0115","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1210\/er.2002-0032","article-title":"Androgen receptor in prostate cancer","volume":"25","author":"Heinlein","year":"2004","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.ijbiomac.2025.149810_bb0120","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/978-1-61779-243-4_2","article-title":"Androgen action during prostate carcinogenesis","volume":"776","author":"Wang","year":"2011","journal-title":"Methods Mol. Biol."},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.149810_bb0125","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1210\/er.2007-0019","article-title":"Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex","volume":"28","author":"Heemers","year":"2007","journal-title":"Endocr. Rev."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149810_bb0130","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/aps.2014.18","article-title":"Androgen receptor: structure, role in prostate cancer and drug discovery","volume":"36","author":"Tan","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.149810_bb0135","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.urolonc.2009.03.016","article-title":"Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease","volume":"27","author":"Mostaghel","year":"2009","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.149810_bb0140","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1146\/annurev-med-051517-011947","article-title":"Treatment of advanced prostate cancer","volume":"70","author":"Teo","year":"2019","journal-title":"Annu. Rev. Med."},{"issue":"7504","key":"10.1016\/j.ijbiomac.2025.149810_bb0145","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/nature13229","article-title":"Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer","volume":"510","author":"Asangani","year":"2014","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.149810_bb0150","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1158\/1541-7786.MCR-15-0472","article-title":"BET bromodomain inhibitors enhance efficacy and disrupt resistance to AR antagonists in the treatment of prostate cancer","volume":"14","author":"Asangani","year":"2016","journal-title":"Mol. Cancer Res."},{"issue":"7570","key":"10.1016\/j.ijbiomac.2025.149810_bb0155","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature14888","article-title":"BET inhibitor resistance emerges from leukaemia stem cells","volume":"525","author":"Fong","year":"2015","journal-title":"Nature"},{"issue":"7327","key":"10.1016\/j.ijbiomac.2025.149810_bb0160","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.149810_bb0165","first-page":"4003","article-title":"CYP19A1 is downregulated by BRD4 and suppresses castration-resistant prostate cancer cell invasion and proliferation by decreasing AR expression","volume":"13","author":"Chen","year":"2023","journal-title":"Am. J. Cancer Res."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149810_bb0170","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/s41467-019-09234-6","article-title":"Metascape provides a biologist-oriented resource for the analysis of systems-level datasets","volume":"10","author":"Zhou","year":"2019","journal-title":"Nat. Commun."},{"issue":"47","key":"10.1016\/j.ijbiomac.2025.149810_bb0175","doi-asserted-by":"crossref","first-page":"7249","DOI":"10.1038\/s41388-019-0930-3","article-title":"Synergy between arsenic trioxide and JQ1 on autophagy in pancreatic cancer","volume":"38","author":"Xu","year":"2019","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.149810_bb0180","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nsmb.3228","article-title":"BRD4 is a histone acetyltransferase that evicts nucleosomes from chromatin","volume":"23","author":"Devaiah","year":"2016","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"25","key":"10.1016\/j.ijbiomac.2025.149810_bb0185","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1038\/sj.onc.1211016","article-title":"Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells","volume":"27","author":"Asim","year":"2008","journal-title":"Oncogene"},{"issue":"1\u20132","key":"10.1016\/j.ijbiomac.2025.149810_bb0190","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.mce.2004.04.013","article-title":"Steroid hormonal regulation of growth, prostate specific antigen secretion, and transcription mediated by the mutated androgen receptor in CWR22Rv1 human prostate carcinoma cells","volume":"222","author":"Attardi","year":"2004","journal-title":"Mol. Cell. Endocrinol."},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.149810_bb0195","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.495","article-title":"Histone acetyltransferase 1 upregulates androgen receptor expression to modulate CRPC cell resistance to enzalutamide","volume":"11","author":"Hong","year":"2021","journal-title":"Clin. Transl. Med."},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.149810_bb0200","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/CM9.0000000000001474","article-title":"Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020","volume":"134","author":"Cao","year":"2021","journal-title":"Chin Med J (Engl)"},{"issue":"11","key":"10.1016\/j.ijbiomac.2025.149810_bb0205","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a030437","article-title":"Transcriptional regulation in prostate cancer","volume":"8","author":"Labbe","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.149810_bb0210","first-page":"158","article-title":"Recent advances in prostate cancer: WNT signaling, chromatin regulation, and transcriptional coregulators","volume":"25","author":"Takahashi","year":"2023","journal-title":"Asian J. Androl."},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.149810_bb0215","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20122883","article-title":"Dysregulated transcriptional control in prostate cancer","volume":"20","author":"Baumgart","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.149810_bb0220","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/13543784.2023.2186851","article-title":"Role of bromodomain and extraterminal (BET) proteins in prostate cancer","volume":"32","author":"Mandl","year":"2023","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"22","key":"10.1016\/j.ijbiomac.2025.149810_bb0225","doi-asserted-by":"crossref","first-page":"6555","DOI":"10.1158\/0008-5472.CAN-16-0559","article-title":"BRD4 regulates breast cancer dissemination through Jagged1\/Notch1 signaling","volume":"76","author":"Andrieu","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijbiomac.2025.149810_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.108793","article-title":"KDM5C is transcriptionally regulated by BRD4 and promotes castration-resistance prostate cancer cell proliferation by repressing PTEN","volume":"114","author":"Hong","year":"2019","journal-title":"Biomed. Pharmacother."},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.149810_bb0235","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/nm.4379","article-title":"Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation","volume":"23","author":"Zhang","year":"2017","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.ijbiomac.2025.149810_bb0240","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1158\/1541-7786.MCR-18-1279","article-title":"BRD4 regulates metastatic potential of castration-resistant prostate cancer through AHNAK","volume":"17","author":"Shafran","year":"2019","journal-title":"Mol. Cancer Res."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.149810_bb0245","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.celrep.2017.12.078","article-title":"BRD4 promotes DNA repair and mediates the formation of TMPRSS2-ERG gene rearrangements in prostate cancer","volume":"22","author":"Li","year":"2018","journal-title":"Cell Rep."},{"issue":"13","key":"10.1016\/j.ijbiomac.2025.149810_bb0250","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1158\/1078-0432.CCR-17-3571","article-title":"Targeting bromodomain and extra-terminal (BET) family proteins in castration-resistant prostate cancer (CRPC)","volume":"24","author":"Welti","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.149810_bb0255","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1158\/1535-7163.MCT-17-0945","article-title":"Plk1 inhibition enhances the efficacy of BET epigenetic reader blockade in castration-resistant prostate cancer","volume":"17","author":"Mao","year":"2018","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149810_bb0260","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1089\/dna.1988.7.27","article-title":"Human aromatase: cDNA cloning, southern blot analysis, and assignment of the gene to chromosome 15","volume":"7","author":"Chen","year":"1988","journal-title":"DNA"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.149810_bb0265","first-page":"342","article-title":"Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis","volume":"15","author":"Simpson","year":"1994","journal-title":"Endocr. Rev."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.149810_bb0270","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1210\/en.2016-1926","article-title":"Inverse regulation of DHT synthesis enzymes 5alpha-reductase types 1 and 2 by the androgen receptor in prostate cancer","volume":"158","author":"Audet-Walsh","year":"2017","journal-title":"Endocrinology"},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.149810_bb0275","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc4016","article-title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","volume":"15","author":"Watson","year":"2015","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.149810_bb0280","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1158\/1078-0432.CCR-13-1100","article-title":"Importance of 5alpha-reductase gene polymorphisms on circulating and intraprostatic androgens in prostate cancer","volume":"20","author":"Levesque","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"14","key":"10.1016\/j.ijbiomac.2025.149810_bb0285","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/j.ejca.2015.06.122","article-title":"SRD5A gene polymorphism in Japanese men predicts prognosis of metastatic prostate cancer with androgen-deprivation therapy","volume":"51","author":"Shiota","year":"2015","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149810_bb0290","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrclinonc.2013.211","article-title":"Future directions in the prevention of prostate cancer","volume":"11","author":"Thompson","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.149810_bb0295","first-page":"56","article-title":"Adverse effects and safety of 5-alpha reductase inhibitors (finasteride, dutasteride): a systematic review","volume":"9","author":"Hirshburg","year":"2016","journal-title":"J. Clin. Aesthet. Dermatol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.149810_bb0300","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.eururo.2010.09.035","article-title":"Prostate cancer detection and dutasteride: utility and limitations of prostate-specific antigen in men with previous negative biopsies","volume":"59","author":"van Leeuwen","year":"2011","journal-title":"Eur. Urol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.149810_bb0305","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.beem.2010.09.008","article-title":"Prostate diseases\u2014role of sex steroids and their inhibitors","volume":"25","author":"Welen","year":"2011","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.149810_bb0310","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.pharmthera.2013.07.003","article-title":"Androgen receptors in hormone-dependent and castration-resistant prostate cancer","volume":"140","author":"Shafi","year":"2013","journal-title":"Pharmacol. Ther."},{"issue":"2\u20133","key":"10.1016\/j.ijbiomac.2025.149810_bb0315","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s10555-013-9474-0","article-title":"Androgen receptor signaling in prostate cancer","volume":"33","author":"Culig","year":"2014","journal-title":"Cancer Metastasis Rev."},{"issue":"9851","key":"10.1016\/j.ijbiomac.2025.149810_bb0320","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/S0140-6736(12)60071-3","article-title":"Androgen insensitivity syndrome","volume":"380","author":"Hughes","year":"2012","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.149810_bb0325","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/aja.2010.89","article-title":"Androgen receptor signaling and mutations in prostate cancer","volume":"12","author":"Koochekpour","year":"2010","journal-title":"Asian J. Androl."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.149810_bb0330","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1124\/pr.58.4.9","article-title":"International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors","volume":"58","author":"Lu","year":"2006","journal-title":"Pharmacol. Rev."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.149810_bb0335","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/ijc.2910480206","article-title":"Androgen receptors in endocrine-therapy-resistant human prostate cancer","volume":"48","author":"van der Kwast","year":"1991","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.149810_bb0340","first-page":"314","article-title":"Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer","volume":"57","author":"Koivisto","year":"1997","journal-title":"Cancer Res."},{"issue":"14","key":"10.1016\/j.ijbiomac.2025.149810_bb0345","first-page":"3068","article-title":"Distant metastases from prostatic carcinoma express androgen receptor protein","volume":"55","author":"Hobisch","year":"1995","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.149810_bb0350","doi-asserted-by":"crossref","first-page":"11511","DOI":"10.1096\/fj.201903167R","article-title":"Unique targeting of androgen-dependent and -independent AR signaling in prostate cancer to overcome androgen resistance","volume":"34","author":"Lim","year":"2020","journal-title":"FASEB J."},{"issue":"18","key":"10.1016\/j.ijbiomac.2025.149810_bb0355","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1007\/s40265-018-1029-9","article-title":"Enzalutamide: a review in castration-resistant prostate cancer","volume":"78","author":"Scott","year":"2018","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149810_bb0360","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nm972","article-title":"Molecular determinants of resistance to antiandrogen therapy","volume":"10","author":"Chen","year":"2004","journal-title":"Nat. Med."},{"issue":"24","key":"10.1016\/j.ijbiomac.2025.149810_bb0365","first-page":"5718","article-title":"Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes","volume":"58","author":"Gregory","year":"1998","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.ijbiomac.2025.149810_bb0370","first-page":"2577","article-title":"Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer","volume":"54","author":"Thalmann","year":"1994","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.149810_bb0375","first-page":"1008","article-title":"Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells","volume":"62","author":"Zegarra-Moro","year":"2002","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149810_bb0380","doi-asserted-by":"crossref","first-page":"20858","DOI":"10.1038\/s41598-022-25335-7","article-title":"Caffeic acid N-[3,5-bis(trifluoromethyl)phenyl] amide as a non-steroidal inhibitor for steroid 5alpha-reductase type 1 using a human keratinocyte cell-based assay and molecular dynamics","volume":"12","author":"Lin","year":"2022","journal-title":"Sci. Rep."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014181302510367X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014181302510367X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T21:44:48Z","timestamp":1768945488000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014181302510367X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":76,"alternative-id":["S014181302510367X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.149810","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Restraining SRD5A1 combined with BRD4 inhibitor delaying prostate cancer progression by decreasing AR expression","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.149810","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"149810"}}